Literature DB >> 24129852

[Challenges of Clostridium difficile infection].

A Ebigbo1, H Messmann.   

Abstract

Clostridium difficile infections remain a problem especially for patients in the intensive care unit. The fact that C. difficile infections are strongly associated with antibiotic therapy calls for more caution in the use of antibiotics, especially in patients with a high risk of developing C. difficle infections. Severe infections and recurrent episodes are usually difficult to manage and therapeutic options are often limited. The method of stool transplantation, though not new, has received more attention in recent years, with studies showing stool transplantation to be a promising and easy method which has high clinical cure rates even for recurrent C. difficile infections. However, more randomised and controlled trials are needed to further study the efficacy of stool transplantation in patients with C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24129852     DOI: 10.1007/s00063-013-0258-7

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  19 in total

1.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea.

Authors:  Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young
Journal:  J Infect Dis       Date:  2008-02-01       Impact factor: 5.226

2.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

3.  Effectiveness of liquid soap vs. chlorhexidine gluconate for the removal of Clostridium difficile from bare hands and gloved hands.

Authors:  K Bettin; C Clabots; P Mathie; K Willard; D N Gerding
Journal:  Infect Control Hosp Epidemiol       Date:  1994-11       Impact factor: 3.254

Review 4.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

5.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

Review 6.  Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature.

Authors:  Anucha Apisarnthanarak; Behzad Razavi; Linda M Mundy
Journal:  Clin Infect Dis       Date:  2002-08-26       Impact factor: 9.079

7.  Emergence of reduced susceptibility to metronidazole in Clostridium difficile.

Authors:  Simon D Baines; Rachael O'Connor; Jane Freeman; Warren N Fawley; Celine Harmanus; Paola Mastrantonio; Ed J Kuijper; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-08-07       Impact factor: 5.790

8.  Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Authors:  Oliver A Cornely; Mark A Miller; Thomas J Louie; Derrick W Crook; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

9.  Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy.

Authors:  Mark A Miller; Thomas Louie; Kathleen Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Yin Kean; Pam Sears
Journal:  BMC Infect Dis       Date:  2013-03-25       Impact factor: 3.090

10.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut.

Authors:  Elaine O Petrof; Gregory B Gloor; Stephen J Vanner; Scott J Weese; David Carter; Michelle C Daigneault; Eric M Brown; Kathleen Schroeter; Emma Allen-Vercoe
Journal:  Microbiome       Date:  2013-01-09       Impact factor: 14.650

View more
  1 in total

1.  Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway.

Authors:  Giuseppe Esposito; Nicola Nobile; Stefano Gigli; Luisa Seguella; Marcella Pesce; Alessandra d'Alessandro; Eugenia Bruzzese; Elena Capoccia; Luca Steardo; Rosario Cuomo; Giovanni Sarnelli
Journal:  Front Pharmacol       Date:  2016-05-09       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.